This randomized , double-blind , placebo-controlled , parallel-group , multicenter study evaluated the effect of once-daily TAA-AQ ( 110 g ) on the growth velocity ( GV ) of children aged 3-9 years with PAR by using stadiometry at baseline ( 4-6 months ) , during treatment ( 12 months ) , and at follow-up ( 2 months ) .